ATROSAB, a humanized antagonistic anti-tumor necrosis factor receptor one-specific antibody
- 1 November 2010
- journal article
- Published by Taylor & Francis in mAbs
- Vol. 2 (6) , 639-647
Abstract
Tumor necrosis factor (TNF) signals through two membrane receptors, TNFR1 and TNFR2, and TNFR1 is known to be the major pathogenic mediator of chronic and acute inflammatory diseases. Present clinical intervention is based on neutralization of the ligand TNF. Selective inhibition of TNF receptor 1 (TNFR1) provides an alternative opportunity to neutralize the pro-inflammatory activity of TNF while maintaining the advantageous immunological responses mediated by TNFR2, including immune regulation, tissue homeostasis and neuroprotection. We recently humanized a mouse anti-human TNFR1 monoclonal antibody exhibiting TNFR1-neutralizing activity. This humanized antibody has been converted into an IgG1 molecule (ATROSAB) containing a modified Fc region previously demonstrated to have greatly reduced effector functions. Purified ATROSAB, produced in CHO cells, showed strong binding to human and rhesus TNFR1-Fc fusion protein and mouse embryonic fibroblasts transfected with a recombinant TNFR1 fusion protein with a...Keywords
This publication has 38 references indexed in Scilit:
- Single chain TNF derivatives with individually mutated receptor binding sites reveal differential stoichiometry of ligand receptor complex formation for TNFR1 and TNFR2Cellular Signalling, 2010
- Dual function of cysteine rich domain (CRD) 1 of TNF receptor type 1: Conformational stabilization of CRD2 and control of receptor responsivenessCellular Signalling, 2010
- Dominant‐Negative Tumor Necrosis Factor Protects fromMycobacterium bovisBacillus Calmette‐Guérin (BCG) and Endotoxin‐Induced Liver Injury without Compromising Host Immunity to BCG andMycobacterium tuberculosisThe Journal of Infectious Diseases, 2009
- Antagonists of TNF action: clinical experience and new developmentsExpert Opinion on Drug Discovery, 2009
- A Humanized Tumor Necrosis Factor Receptor 1 (TNFR1)-specific Antagonistic Antibody for Selective Inhibition of Tumor Necrosis Factor (TNF) ActionJournal of Immunotherapy, 2008
- Improved Pharmacokinetics of Recombinant Bispecific Antibody Molecules by Fusion to Human Serum AlbuminJournal of Biological Chemistry, 2007
- Anti-TNF Antibody Therapy in Rheumatoid Arthritis and the Risk of Serious Infections and MalignanciesJAMA, 2006
- Tumor necrosis factor signalingCell Death & Differentiation, 2003
- Recombinant human IgG molecules lacking Fcγ receptor I binding and monocyte triggering activitiesEuropean Journal of Immunology, 1999
- Sex‐Linked differences in susceptibility of cynomolgus monkeys to type II collagen–induced arthritis. Evidence that epitope‐specific immune suppression is involved in the regulation of type II collagen autoantibody formationArthritis & Rheumatism, 1989